Tilray | TRLY - Net Income

Stock Price
9.23
Daily Change
-0.23 -2.43%
Monthly
-3.75%
Yearly
1,237.68%
Q2 Forecast
9.04

Tilray reported $-44.93M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acasti Pharma USD -938K 2.42M Sep/2025
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Alaunos Therapeutics USD -1.16M 108K Sep/2025
Aurora Cannabis CAD 1.82M 53.29M Dec/2025
Avita Medical AUD -11.62M 1.7M Dec/2025
Canopy Growth CAD -62.63M 60.99M Dec/2025
Cronos Group USD -1.82M 24.14M Dec/2025
Dianthus Therapeutics USD -64.43M 27.67M Dec/2025
Divis Laboratories Ltd INR 5.83B 1.06B Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
IQVIA Holdings USD 514M 183M Dec/2025
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Moderna USD -200M 625M Sep/2025
Organigram Holdings CAD 19.97M 57.93M Dec/2025
Organon & Co USD 160M 15M Sep/2025
Revvity USD 98.36M 51.71M Dec/2025
Tectonic Therapeutic USD -19.23M 186K Dec/2025
Tilray USD -44.93M 44.61M Sep/2025
Viatris USD -340.1M 211.9M Dec/2025
Xeris Pharmaceuticals USD 11.08M 10.46M Dec/2025
Zealand Pharma A/S -379.12M 25.12M Dec/2025